Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption
Anne Sophie Sølling, Torben Harsløf, Niklas Rye Jørgensen, Bente Langdahl
Topics & Concepts
DenosumabRANKLMedicineBone resorptionDiscontinuationResorptionBone Density Conservation AgentsInternal medicineEndocrinologyRheumatologyOsteoclastCancer researchOsteoporosisReceptorBone mineralActivator (genetics)Bone Metabolism and DiseasesBone health and osteoporosis researchBone health and treatments